Compounded Peptides ·
Retatrutide sits in a very different legal position from tirzepatide. Because retatrutide has not been approved by the FDA, there is no approved reference drug on which a traditional 503A compound can be based. Retatrutide is also not on the 503A or 503B bulks list. This means that, under current law, there is no lawful route for a US compounding pharmacy to prepare patient-specific retatrutide injections for therapeutic use. What is marketed as 'compounded retatrutide' in 2026 is typically being sold either as a 'research chemical' for laboratory use, or through channels that the FDA has increasingly characterized as unapproved new drug distribution.
Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.